dermatology
DLQI (Dermatology Life Quality Index)
Patient-reported quality of life questionnaire for skin disease. DLQI >10 indicates very large impact; combined with PASI triggers biologic eligibility.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Dupilumab · Biologic (IL-4 / IL-13 receptor antagonist)
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Salicylic Acid · Keratolytic — Warts / Psoriasis / Hyperkeratosis
- Ixekizumab · IL-17A Inhibitor — Psoriasis
- Guselkumab · IL-23 Inhibitor — Psoriasis
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.